AUTOLUS LIMITED

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of CD19 Targeted CAR T Cell Therapy in Patients With Severe, Refractory Systemic Lupus Erythematosus (SLE)

Phase 1

Recruiting

Conditions: Systemic Lupus Erythematosus

Interventions: Biological: Obecabtagene autoleucel (obe-cel)

First Posted Date: 2024-03-27

Last Posted Date: 2024-06-26

Lead Sponsor: Autolus Limited

Target Recruit Count: 12

Registration Number: NCT06333483

Locations: 🇬🇧
University College London Hospitals NHS Foundation Trust, London, United Kingdom
🇪🇸
Hospital Universitari Vall Hebrón, Barcelona, Spain
🇬🇧
Manchester Royal Infirmary, Manchester University NHS Foundation Trust,, Manchester, United Kingdom

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

Phase 1

Recruiting

Conditions: Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

Interventions: Biological: AUTO1

First Posted Date: 2023-12-15

Last Posted Date: 2024-06-12

Lead Sponsor: Autolus Limited

Target Recruit Count: 24

Registration Number: NCT06173518

Locations: 🇺🇸
Methodist Children's Hospital, San Antonio, Texas, United States
🇪🇸
Hospital Vall d'Hebron, Barcelona, Spain
🇬🇧
Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom

and more 3 locations

A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Phase 1

Active, not recruiting

Conditions: Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

First Posted Date: 2020-05-27

Last Posted Date: 2024-06-26

Lead Sponsor: Autolus Limited

Target Recruit Count: 153

Registration Number: NCT04404660

Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells

Phase 2

Conditions: T Cell Lymphoma
ALL, Adult and Pediatric
Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy
DLBCL
Multiple Myeloma

Interventions: Biological: AUTO CAR T cell therapy

First Posted Date: 2018-08-14

Last Posted Date: 2024-06-26

Lead Sponsor: Autolus Limited

Target Recruit Count: 500

Registration Number: NCT03628612

Locations: 🇺🇸
University of Miami, Miami, Florida, United States
🇬🇧
University College London Hospitals NHS Foundation Trust, London, United Kingdom
🇺🇸
St David's South Austin Medical Center, Austin, Texas, United States

and more 5 locations

Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma

Phase 1

Recruiting

Conditions: Angioimmunoblastic T-cell Lymphoma
Anaplastic Large Cell Lymphoma
Peripheral T-Cell Lymphoma, Not Otherwise Specified
T Cell Non-Hodgkin Lymphoma

Interventions: Biological: AUTO4

First Posted Date: 2018-07-18

Last Posted Date: 2023-02-21

Lead Sponsor: Autolus Limited

Target Recruit Count: 200

Registration Number: NCT03590574

Locations: 🇬🇧
Manchester Royal Infirmary Hospital, Manchester, United Kingdom
🇪🇸
Vall d'Hebron Institute of Oncology, Barcelona, Spain
🇬🇧
Queen Elizabeth University Hospital, Glasgow, United Kingdom

and more 2 locations

CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)

Phase 1

Completed

Conditions: B-cell Acute Lymphoblastic Leukemia
Recurrent Childhood Acute Lymphoblastic Leukemia
Refractory Childhood Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia

Interventions: Biological: AUTO3 (CD19/22 CAR T cells

First Posted Date: 2017-09-21

Last Posted Date: 2021-02-01

Lead Sponsor: Autolus Limited

Target Recruit Count: 23

Registration Number: NCT03289455

Locations: 🇬🇧
University College London Hospitals NHS Foundation Trust, London, United Kingdom
🇬🇧
Royal Manchester Children's Hospital, Manchester, United Kingdom
🇬🇧
Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom

CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma

Phase 1

Completed

Conditions: Diffuse Large B Cell Lymphoma
Relapsed Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
DLBCL

Interventions: Biological: AUTO3

First Posted Date: 2017-09-19

Last Posted Date: 2024-01-08

Lead Sponsor: Autolus Limited

Target Recruit Count: 73

Registration Number: NCT03287817

Locations: 🇬🇧
University College London Hospitals NHS Foundation Trust, London, United Kingdom
🇬🇧
The Beatson West of Scotland Cancer Centre / Queen Elizabeth University Hospital, Glasgow, United Kingdom
🇬🇧
Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom

and more 8 locations

APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Biological: AUTO2

First Posted Date: 2017-09-19

Last Posted Date: 2020-10-23

Lead Sponsor: Autolus Limited

Target Recruit Count: 12

Registration Number: NCT03287804

Locations: 🇳🇱
VU University Medical Centre Amsterdam, Amsterdam, Netherlands
🇬🇧
University College London Hospitals NHS Foundation Trust, London, United Kingdom
🇬🇧
Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom

and more 1 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy